Siemens healthcare diagnostics inc.Has confirmed customer complaints of falsely depressed enzymatic creatinine (ezcr) results when ezcr is processed from open wells of enzymatic creatinine (ezcr) flex® reagent cartridge that is in close proximity to open wells of phosphorous (phos) flex® reagent cartridge.The falsely depressed ezcr results are caused by a phos reagent vapor interaction with the ezcr reagent.An urgent medical device correction for the phos flex® reagent cartridge (df61), communication #13-03, was issued in february, 2013 to impacted customers.The communication provided remedial actions to customers to either avoid the reagent interactions or to discontinue the use of either phos or ezcr on their dimension® clinical chemistry system.Siemens has confirmed that the customer received the communication.There is a note in ezcr® reagent cartridge carton, instructing users not run ezcr and phos on the same dimension® system.The note also contains a reference to the february, 2013 communication.Siemens has determined that the customer was running phos on the system at the time of the obtaining depressed urine creatinine qc results.A revised phosphorous method (df61a) which does not impact ezcr was introduced in december, 2014.The customer was sent the revised phosphorous method (df61a) and has instituted use of the revised phos df61a but has continued to use their remaining inventory of df61 for urine creatinine testing.This account has reported the potential for reporting depressed urine creatinine results by keeping both ezcr and phos df61 reagent cartridges on their dimension xpand instrument system.The account as instituted a practice of aborting the use of an ezcr reagent well set when qc is out of laboratory range and moving to a new reagent well set and repeating qc.If qc was within range, patient specimens were run as single samples.There is no record of any patient impact known at this time.The instrument is performing within specifications.
|